PharmacyCodes



Dobutamine [Usan] en es it fr

Dobutamine [Usan] Brand names, Dobutamine [Usan] Analogs

Dobutamine [Usan] Brand Names Mixture

  • No information avaliable

Dobutamine [Usan] Chemical_Formula

C18H23NO3

Dobutamine [Usan] RX_link

http://www.rxlist.com/cgi/generic3/dobutamine.htm

Dobutamine [Usan] fda sheet

Dobutamine [Usan] msds (material safety sheet)

Dobutamine [Usan] Synthesis Reference

No information avaliable

Dobutamine [Usan] Molecular Weight

301.38 g/mol

Dobutamine [Usan] Melting Point

No information avaliable

Dobutamine [Usan] H2O Solubility

No information avaliable

Dobutamine [Usan] State

Solid

Dobutamine [Usan] LogP

3.489

Dobutamine [Usan] Dosage Forms

Liquid

Dobutamine [Usan] Indication

For inotropic support in the short- term treatment of patients with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures

Dobutamine [Usan] Pharmacology

Dobutamine is a direct-acting inotropic agent whose primary activity results from stimulation of the beta-adrenoceptors of the heart while producing comparatively mild chronotropic, hypertensive, arrhythmogenic, and vasodilative effects. Dobutamine acts primarily on beta-1 adrenergic receptors, with little effect on beta-2 or alpha receptors. It does not cause the release of endogenous norepinephrine, as does dopamine. Dobutamine is indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of patients with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures.

Dobutamine [Usan] Absorption

No information avaliable

Dobutamine [Usan] side effects and Toxicity

No information avaliable

Dobutamine [Usan] Patient Information

No information avaliable

Dobutamine [Usan] Organisms Affected

Humans and other mammals